PLRX
PLIANT THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$0.86
−0.13%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +56.4%
- EBIT
- +55.7%
- EPS
- +56.2%
- Free cash flow
- +58.5%
- Operating cash flow
- +58.1%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- -7.4%
- EPS
- -4.0%
Three-year CAGR
- Revenue
- —
- EBITDA
- +29.3%
- EBIT
- +34.3%
- Net income
- +29.0%
- EPS
- +30.0%
- Free cash flow
- +19.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026